MedTrace Logo

A Study of SEA-CD40 Given With Other Drugs in Cancers

NCT04993677 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2025-05-11

Study results available
· View outcomes & findings →

Summary

This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug.

There are 2 parts in this trial. In one part, participants have melanoma that has come back after treatment or can't be removed by surgery. Participants in this part will get SEA-CD40 and pembrolizumab. In the other part, participants have non-small cell lung cancer (NSCLC) that has spread through their body. These participants will get SEA-CD40, pembrolizumab, carboplatin, and pemetrexed.

Conditions

  • Melanoma
  • Carcinoma, Non-Small- Cell Lung

Interventions

DRUG

SEA-CD40

Given into the vein (IV; intravenously); schedule is cohort-specific

DRUG

pembrolizumab (KEYTRUDA®)

Given by IV; schedule is cohort-specific.

DRUG

pemetrexed

Given by IV on Day 1 of each 21-day cycle.

DRUG

carboplatin

Given by IV on Day 1 of Cycles 1-4. Each cycle will be 21 days long.

Sponsors & Collaborators

Principal Investigators

  • Jonathan Hayman, MD · Seagen Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-06
Primary Completion
2024-01-03
Completion
2024-11-25
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Germany
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04993677 on ClinicalTrials.gov